Affiliation:
1. Laboratoire de Pharmacocinétique, Pharmacie Carémeau, Centre Hospitalier Universitaire, Nimes, France.
Abstract
The pharmacokinetic parameters of amikacin and ceftazidime were assessed in four patients undergoing hemofiltration for septic shock. The parameters were assessed during hemofiltration and in the interim period. The concentration-time profiles of these two drugs in plasma, urine, and ultrafiltrate were investigated after intravenous perfusion (30 min). In all cases a 1-g dose of ceftazidime was administered; for amikacin, the dosage regimen was adjusted according to the patient's amikacin levels (250 to 750 mg). Concentrations of drug in all samples were assayed by high-performance liquid chromatography with UV detection for ceftazidime and by enzyme multiplied immunoassay for amikacin. The elimination half-life (t1/2) and the total clearance of amikacin ranged from 31.1 to 138.2 h and from 5.4 to 8.9 ml/min, respectively, during the interhemofiltration period in anuric patients. Hemofiltration substantially decreased the t1/2 (3.5 +/- 0.49 h) and increased the total clearance (89.5 +/- 11.8 ml/min). The hemofiltration clearance of amikacin represented 71% of the total clearance, and the hemofiltration process removed, on average, 60% of the dose. During hemofiltration, the elimination t1/2 of ceftazidime (2.8 +/- 0.69 h) was greatly reduced and the total clearance increased (74.2 +/- 11.2 ml/min) compared with those in the interhemofiltration period (9 to 43.7 h and 7.4 to 16.8 ml/min, respectively). About 55% of the administered dose was recovered in the filtrate, and the hemofiltration clearance of ceftazidime was 46 +/- 14.3 ml/min. A redistribution phenomenon (rebound) in the amikacin and ceftazidime concentrations in plasma (35 and 28%, respectively) was reported after hemofiltration in two patients. The MICs for 90% of the most important pathogens were exceeded by the concentrations of the two drugs in plasma during the whole treatment of these patients.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference26 articles.
1. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration;Armendariz E.;Crit. Care Med.,1990
2. Distribution of ceftazidime in ascite fluid;Benoni G.;Antimicrob. Agents Chemother.,1984
3. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability;Bressolle F.;Antimicrob. Agents Chemother.,1992
4. Burchardi H. 1989. Update in intensive care and emergency medicine p. 340-347. In J. L. Vincent (ed.). Springer-Verlag Berlin.
5. Daikos G. K. J. Kosmidis C. Stathakis H. Giamarellou E. Douzinas and S. Kastanakis. 1982. Ceftazidime: a new-broad spectrum antipseudomonal cephalosporin: in vitro activity human pharmacokinetics and therapeutic efficacy p. 499-501. In Current chemotherapy and immunotherapy. Proceedings of the 12th International Congress of Chemotherapy. American Society for Microbiology Washington D.C.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献